Taivex Therapeutics Corporation
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. T-1101: Global first-in-class Hec1/Nek2 targeted small molecule inhibitor
2. T-1201: Novel targeted small molecule-SN-38 conjugate anticancer drug
3. T-1301: Multi-targeted tyrosine kinase inhibitor
4. T-1501: Novel small molecule-DM-1 conjugate targeted anticancer drug
(The content above was translated by AI.)
2. T-1201: Novel targeted small molecule-SN-38 conjugate anticancer drug
3. T-1301: Multi-targeted tyrosine kinase inhibitor
4. T-1501: Novel small molecule-DM-1 conjugate targeted anticancer drug
(The content above was translated by AI.)
Founded Year
2010
Unified Business No.
25104214
Status
Active
Number of Employees
0
Total Paid-in
Capital
707,399,260 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taivex Therapeutics Inc. is a proprietary technology platforms to identify compounds that inhibit the Hec1-Nek2 interactions
